Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.
Identifieur interne : 000691 ( PubMed/Checkpoint ); précédent : 000690; suivant : 000692Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.
Auteurs : Miguel Ulla [France] ; Jean Marie Bonny ; Lemlih Ouchchane ; Isabelle Rieu ; Beatrice Claise ; Franck DurifSource :
- PloS one [ 1932-6203 ] ; 2013.
English descriptors
- KwdEn :
- Aged, Basal Ganglia (metabolism), Basal Ganglia (pathology), Biomarkers (metabolism), Case-Control Studies, Disease Progression, Female, Follow-Up Studies, Humans, Iron (metabolism), Magnetic Resonance Imaging, Male, Middle Aged, Parkinson Disease (diagnosis), Parkinson Disease (metabolism), Parkinson Disease (pathology), Putamen (metabolism), Putamen (pathology), Reticular Formation (metabolism), Reticular Formation (pathology), Substantia Nigra (metabolism), Substantia Nigra (pathology).
- MESH :
- chemical , metabolism : Biomarkers, Iron.
- diagnosis : Parkinson Disease.
- metabolism : Basal Ganglia, Parkinson Disease, Putamen, Reticular Formation, Substantia Nigra.
- pathology : Basal Ganglia, Parkinson Disease, Putamen, Reticular Formation, Substantia Nigra.
- Aged, Case-Control Studies, Disease Progression, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Male, Middle Aged.
Abstract
To study changes of iron content in basal ganglia in Parkinson's disease (PD) through a three-year longitudinal follow-up of the effective transverse relaxation rate R2*, a validated MRI marker of brain iron content which can be rapidly measured under clinical conditions.
DOI: 10.1371/journal.pone.0057904
PubMed: 23469252
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:23469252Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.</title><author><name sortKey="Ulla, Miguel" sort="Ulla, Miguel" uniqKey="Ulla M" first="Miguel" last="Ulla">Miguel Ulla</name><affiliation wicri:level="3"><nlm:affiliation>CHU Clermont-Ferrand, Service de Neurologie A, Clermont-Ferrand, France. mulla@chu-clermontferrand.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CHU Clermont-Ferrand, Service de Neurologie A, Clermont-Ferrand</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Auvergne (région administrative)</region><settlement type="city">Clermont-Ferrand</settlement></placeName></affiliation></author><author><name sortKey="Bonny, Jean Marie" sort="Bonny, Jean Marie" uniqKey="Bonny J" first="Jean Marie" last="Bonny">Jean Marie Bonny</name></author><author><name sortKey="Ouchchane, Lemlih" sort="Ouchchane, Lemlih" uniqKey="Ouchchane L" first="Lemlih" last="Ouchchane">Lemlih Ouchchane</name></author><author><name sortKey="Rieu, Isabelle" sort="Rieu, Isabelle" uniqKey="Rieu I" first="Isabelle" last="Rieu">Isabelle Rieu</name></author><author><name sortKey="Claise, Beatrice" sort="Claise, Beatrice" uniqKey="Claise B" first="Beatrice" last="Claise">Beatrice Claise</name></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23469252</idno><idno type="pmid">23469252</idno><idno type="doi">10.1371/journal.pone.0057904</idno><idno type="wicri:Area/PubMed/Corpus">000803</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000803</idno><idno type="wicri:Area/PubMed/Curation">000767</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000767</idno><idno type="wicri:Area/PubMed/Checkpoint">000767</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000767</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.</title><author><name sortKey="Ulla, Miguel" sort="Ulla, Miguel" uniqKey="Ulla M" first="Miguel" last="Ulla">Miguel Ulla</name><affiliation wicri:level="3"><nlm:affiliation>CHU Clermont-Ferrand, Service de Neurologie A, Clermont-Ferrand, France. mulla@chu-clermontferrand.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CHU Clermont-Ferrand, Service de Neurologie A, Clermont-Ferrand</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Auvergne (région administrative)</region><settlement type="city">Clermont-Ferrand</settlement></placeName></affiliation></author><author><name sortKey="Bonny, Jean Marie" sort="Bonny, Jean Marie" uniqKey="Bonny J" first="Jean Marie" last="Bonny">Jean Marie Bonny</name></author><author><name sortKey="Ouchchane, Lemlih" sort="Ouchchane, Lemlih" uniqKey="Ouchchane L" first="Lemlih" last="Ouchchane">Lemlih Ouchchane</name></author><author><name sortKey="Rieu, Isabelle" sort="Rieu, Isabelle" uniqKey="Rieu I" first="Isabelle" last="Rieu">Isabelle Rieu</name></author><author><name sortKey="Claise, Beatrice" sort="Claise, Beatrice" uniqKey="Claise B" first="Beatrice" last="Claise">Beatrice Claise</name></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Basal Ganglia (metabolism)</term><term>Basal Ganglia (pathology)</term><term>Biomarkers (metabolism)</term><term>Case-Control Studies</term><term>Disease Progression</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Iron (metabolism)</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson Disease (pathology)</term><term>Putamen (metabolism)</term><term>Putamen (pathology)</term><term>Reticular Formation (metabolism)</term><term>Reticular Formation (pathology)</term><term>Substantia Nigra (metabolism)</term><term>Substantia Nigra (pathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Biomarkers</term><term>Iron</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia</term><term>Parkinson Disease</term><term>Putamen</term><term>Reticular Formation</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Basal Ganglia</term><term>Parkinson Disease</term><term>Putamen</term><term>Reticular Formation</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Case-Control Studies</term><term>Disease Progression</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To study changes of iron content in basal ganglia in Parkinson's disease (PD) through a three-year longitudinal follow-up of the effective transverse relaxation rate R2*, a validated MRI marker of brain iron content which can be rapidly measured under clinical conditions.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23469252</PMID><DateCreated><Year>2013</Year><Month>03</Month><Day>07</Day></DateCreated><DateCompleted><Year>2013</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>3</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.</ArticleTitle><Pagination><MedlinePgn>e57904</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0057904</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To study changes of iron content in basal ganglia in Parkinson's disease (PD) through a three-year longitudinal follow-up of the effective transverse relaxation rate R2*, a validated MRI marker of brain iron content which can be rapidly measured under clinical conditions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-seven PD patients and 26 controls were investigated by a first MRI (t0). Longitudinal analysis was conducted among the 18 controls and 14 PD patients who underwent a second MRI (t1) 3 years after. The imaging protocol consisted in 6 gradient echo images obtained at different echo-times for mapping R2*. Quantitative exploration of basal ganglia was performed by measuring the variation of R2* [R2*(t1) - R2*(t0)] in several regions of interest.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During the three-year evolution of PD, R2* increased in Substantia nigra (SN) (by 10.2% in pars compacta, p = 0.001, and 8.1% in pars reticulata, p = 0.013) and in the caudal putamen (11.4%, p = 0.011), without significant change in controls. Furthermore, we showed a positive correlation between the variation of R2* and the worsening of motor symptoms of PD (p = 0.028).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Significant variation of R2* was longitudinally observed in the SN and caudal putamen of patients with PD evolving over a three-year period, emphasizing its interest as a biomarker of disease progression. Our results suggest that R2* MRI follow-up could be an interesting tool for individual assessment of neurodegeneration due to PD, and also be useful for testing the efficiency of disease-modifying treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ulla</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CHU Clermont-Ferrand, Service de Neurologie A, Clermont-Ferrand, France. mulla@chu-clermontferrand.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonny</LastName><ForeName>Jean Marie</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Ouchchane</LastName><ForeName>Lemlih</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Rieu</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Claise</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Durif</LastName><ForeName>Franck</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Brain. 2000 Dec;123 Pt 12:2423-31</RefSource><PMID Version="1">11099445</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Can J Neurol Sci. 1998 Feb;25(1):44-7</RefSource><PMID Version="1">9532280</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Free Radic Biol Med. 2003 Sep 1;35(5):540-7</RefSource><PMID Version="1">12927603</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Neurosci. 2004 Nov;5(11):863-73</RefSource><PMID Version="1">15496864</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52</RefSource><PMID Version="1">2841426</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1991 Jun 1;337(8753):1321-4</RefSource><PMID Version="1">1674304</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 1991 Aug;114 ( Pt 4):1953-75</RefSource><PMID Version="1">1832073</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci Res. 1994 Mar 1;37(4):461-5</RefSource><PMID Version="1">8021970</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Magn Reson Med. 1994 Dec;32(6):749-63</RefSource><PMID Version="1">7869897</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1995 Jun;52(6):583-8</RefSource><PMID Version="1">7763206</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1995 Jun;45(6):1138-43</RefSource><PMID Version="1">7783878</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Magn Reson B. 1996 Apr;111(1):61-9</RefSource><PMID Version="1">8620286</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Magn Reson Imaging. 1997;15(1):29-35</RefSource><PMID Version="1">9084022</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Exp Med Biol. 1997;413:129-37</RefSource><PMID Version="1">9238493</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Magn Reson Imaging. 1999 Feb;17(2):213-22</RefSource><PMID Version="1">10215476</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiology. 1999 Mar;210(3):759-67</RefSource><PMID Version="1">10207479</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2005 Feb;57(2):176-9</RefSource><PMID Version="1">15668963</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol. 2006 Jan;253(1):26-32</RefSource><PMID Version="1">15981079</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Ther. 2006 Jan;28(1):1-12</RefSource><PMID Version="1">16490575</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Suppl. 2006;(70):133-42</RefSource><PMID Version="1">17017520</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Aging. 2007 Mar;28(3):414-23</RefSource><PMID Version="1">16563566</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Feb 15;22(3):334-40</RefSource><PMID Version="1">17149719</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Suppl. 2006;(71):201-4</RefSource><PMID Version="1">17447430</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2008 Mar 1;40(1):35-42</RefSource><PMID Version="1">18180169</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2008 Apr 15;70(16 Pt 2):1411-7</RefSource><PMID Version="1">18172063</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AJNR Am J Neuroradiol. 2008 May;29(5):950-5</RefSource><PMID Version="1">18272561</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Magn Reson Imaging. 2008 Nov;28(5):1061-7</RefSource><PMID Version="1">18972346</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18578-83</RefSource><PMID Version="1">19011085</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2009 Apr;8(4):382-97</RefSource><PMID Version="1">19296921</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2009 Oct 1;47(4):1237-43</RefSource><PMID Version="1">19497378</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Magn Reson Med. 2009 Nov;62(5):1326-30</RefSource><PMID Version="1">19780172</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2010 Jun;51(2):512-20</RefSource><PMID Version="1">20211271</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2010 Nov;133(11):3423-33</RefSource><PMID Version="1">20736190</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AJNR Am J Neuroradiol. 2011 Apr;32(4):688-94</RefSource><PMID Version="1">21183619</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 Aug 1;26(9):1627-32</RefSource><PMID Version="1">21618607</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1112-8</RefSource><PMID Version="1">21593513</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2001 Oct;58(10):1611-5</RefSource><PMID Version="1">11594919</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011699" MajorTopicYN="N">Putamen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012154" MajorTopicYN="N">Reticular Formation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3585727</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>08</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>01</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23469252</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0057904</ArticleId><ArticleId IdType="pii">PONE-D-12-23939</ArticleId><ArticleId IdType="pmc">PMC3585727</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Auvergne (région administrative)</li><li>Auvergne-Rhône-Alpes</li></region><settlement><li>Clermont-Ferrand</li></settlement></list><tree><noCountry><name sortKey="Bonny, Jean Marie" sort="Bonny, Jean Marie" uniqKey="Bonny J" first="Jean Marie" last="Bonny">Jean Marie Bonny</name><name sortKey="Claise, Beatrice" sort="Claise, Beatrice" uniqKey="Claise B" first="Beatrice" last="Claise">Beatrice Claise</name><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name><name sortKey="Ouchchane, Lemlih" sort="Ouchchane, Lemlih" uniqKey="Ouchchane L" first="Lemlih" last="Ouchchane">Lemlih Ouchchane</name><name sortKey="Rieu, Isabelle" sort="Rieu, Isabelle" uniqKey="Rieu I" first="Isabelle" last="Rieu">Isabelle Rieu</name></noCountry><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Ulla, Miguel" sort="Ulla, Miguel" uniqKey="Ulla M" first="Miguel" last="Ulla">Miguel Ulla</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000691 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000691 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:23469252
|texte= Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:23469252" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |